[
  {
    "ts": null,
    "headline": "Amgen: Biosimilars And Rare Disease Pipeline Crucial To Overcome Patent Cliff Concerns",
    "summary": "Amgen's expanding rare disease and biosimilar portfolios, coupled with growth potential and dividend history make AMGN stock a strong long-term opportunity.",
    "url": "https://finnhub.io/api/news?id=dd95196df08df83dcb835a89e877361f36e0ec6beb9048b6078e84cf1c31a0ac",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752622845,
      "headline": "Amgen: Biosimilars And Rare Disease Pipeline Crucial To Overcome Patent Cliff Concerns",
      "id": 135959071,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1401241138/image_1401241138.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Amgen's expanding rare disease and biosimilar portfolios, coupled with growth potential and dividend history make AMGN stock a strong long-term opportunity.",
      "url": "https://finnhub.io/api/news?id=dd95196df08df83dcb835a89e877361f36e0ec6beb9048b6078e84cf1c31a0ac"
    }
  },
  {
    "ts": null,
    "headline": "What Makes Amgen (AMGN) a New Buy Stock",
    "summary": "Amgen (AMGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.",
    "url": "https://finnhub.io/api/news?id=b44d38097d2519786d59afc133ac8d48a56b4855fd6bc3f2d5d00bb9f8330487",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752595203,
      "headline": "What Makes Amgen (AMGN) a New Buy Stock",
      "id": 135965430,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (AMGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.",
      "url": "https://finnhub.io/api/news?id=b44d38097d2519786d59afc133ac8d48a56b4855fd6bc3f2d5d00bb9f8330487"
    }
  },
  {
    "ts": null,
    "headline": "Are Medical Stocks Lagging  Amgen (AMGN) This Year?",
    "summary": "Here is how Amgen (AMGN) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.",
    "url": "https://finnhub.io/api/news?id=8f269ff7e1dc4757dd474ae8cc434c20fc6682b55d4aea9f4e93a45bc75536ef",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752586801,
      "headline": "Are Medical Stocks Lagging  Amgen (AMGN) This Year?",
      "id": 135965431,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Here is how Amgen (AMGN) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.",
      "url": "https://finnhub.io/api/news?id=8f269ff7e1dc4757dd474ae8cc434c20fc6682b55d4aea9f4e93a45bc75536ef"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=ac22fbf4a974fbd7174372bc4cb63d031f30c657a39ace0a39aa4c694e8e8427",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752584403,
      "headline": "Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It",
      "id": 135965432,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=ac22fbf4a974fbd7174372bc4cb63d031f30c657a39ace0a39aa4c694e8e8427"
    }
  },
  {
    "ts": null,
    "headline": "How To Buy Stocks Using Technical Analysis Of Past Winners To Spot Emerging Growth Stocks",
    "summary": "Knowing how to buy stocks for big gains starts with technical analysis of the best growthstocks of all time. These case studies show you how.",
    "url": "https://finnhub.io/api/news?id=eee17c948c8542876a34191b9df5b976b2112df42188c0da8d6b56e3d8ae4ffe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752583175,
      "headline": "How To Buy Stocks Using Technical Analysis Of Past Winners To Spot Emerging Growth Stocks",
      "id": 135962143,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Knowing how to buy stocks for big gains starts with technical analysis of the best growthstocks of all time. These case studies show you how.",
      "url": "https://finnhub.io/api/news?id=eee17c948c8542876a34191b9df5b976b2112df42188c0da8d6b56e3d8ae4ffe"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Plunges 20% YTD: How Should Investors Play the Stock?",
    "summary": "NVO shares fall 19.9% year to date amid weak CagriSema data, CEO exit and rising pressure from rivals in obesity care.",
    "url": "https://finnhub.io/api/news?id=5601753e6705c84146473dc1f83434e4b9cbffe179037df81ac46c3a8241cc62",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752582840,
      "headline": "Novo Nordisk Plunges 20% YTD: How Should Investors Play the Stock?",
      "id": 135959025,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "NVO shares fall 19.9% year to date amid weak CagriSema data, CEO exit and rising pressure from rivals in obesity care.",
      "url": "https://finnhub.io/api/news?id=5601753e6705c84146473dc1f83434e4b9cbffe179037df81ac46c3a8241cc62"
    }
  },
  {
    "ts": null,
    "headline": "2025 Mid-year Highlights In Canadian Life Sciences IP And Regulatory Law",
    "summary": "In the first half of 2025, the Rx IP Update team reported on a number of developments in Canadian life sciences IP and regulatory law. Below are our top stories. 1. Alexion awarded injunction against...",
    "url": "https://finnhub.io/api/news?id=b628b734caf02c767cd55e5add956dc1a312114511782c51d6d80131d93d21bf",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752581348,
      "headline": "2025 Mid-year Highlights In Canadian Life Sciences IP And Regulatory Law",
      "id": 135948533,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "In the first half of 2025, the Rx IP Update team reported on a number of developments in Canadian life sciences IP and regulatory law. Below are our top stories. 1. Alexion awarded injunction against...",
      "url": "https://finnhub.io/api/news?id=b628b734caf02c767cd55e5add956dc1a312114511782c51d6d80131d93d21bf"
    }
  },
  {
    "ts": null,
    "headline": "Dow's 267-point fall led by losses in American Express, UnitedHealth stocks",
    "summary": "Dow's 267-point fall led by losses in American Express, UnitedHealth stocks",
    "url": "https://finnhub.io/api/news?id=46ab8f4b86d2dde50ce7150c01953717a2b163b0c9ffe0eecaf66ec848ffafe1",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752575820,
      "headline": "Dow's 267-point fall led by losses in American Express, UnitedHealth stocks",
      "id": 135975426,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Dow's 267-point fall led by losses in American Express, UnitedHealth stocks",
      "url": "https://finnhub.io/api/news?id=46ab8f4b86d2dde50ce7150c01953717a2b163b0c9ffe0eecaf66ec848ffafe1"
    }
  },
  {
    "ts": null,
    "headline": "Chronic Rhinosinusitis with Nasal Polyps Market Analysis and Forecast Report 2025-2035, Featuring AstraZeneca, Amgen, GlaxoSmithKline, Keymed Biosciences, Biohaven Pharmaceuticals, Sanofi, and More",
    "summary": "The global chronic rhinosinusitis with nasal polyps market is experiencing growth, driven by the uptake of biologic therapies like dupilumab and mepolizumab that effectively target inflammatory pathways. This market expansion is fueled by the rising prevalence of the condition, better diagnosis, and awareness, despite challenges like high treatment costs and limited access in developing regions. The market, forecasted for significant growth between 2025-2035, sees North America as a dominant pla",
    "url": "https://finnhub.io/api/news?id=bacc68cb9dd2c5d0201ef37fad3db621f571d7a28132f6c08a6dde3239e199f9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752571560,
      "headline": "Chronic Rhinosinusitis with Nasal Polyps Market Analysis and Forecast Report 2025-2035, Featuring AstraZeneca, Amgen, GlaxoSmithKline, Keymed Biosciences, Biohaven Pharmaceuticals, Sanofi, and More",
      "id": 135940128,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The global chronic rhinosinusitis with nasal polyps market is experiencing growth, driven by the uptake of biologic therapies like dupilumab and mepolizumab that effectively target inflammatory pathways. This market expansion is fueled by the rising prevalence of the condition, better diagnosis, and awareness, despite challenges like high treatment costs and limited access in developing regions. The market, forecasted for significant growth between 2025-2035, sees North America as a dominant pla",
      "url": "https://finnhub.io/api/news?id=bacc68cb9dd2c5d0201ef37fad3db621f571d7a28132f6c08a6dde3239e199f9"
    }
  },
  {
    "ts": null,
    "headline": "Amgen: Great Starting Yield For This Wealth Compounder",
    "summary": "Amgen combines patent protection, a robust pipeline, and strong execution for defensive investment.",
    "url": "https://finnhub.io/api/news?id=43424ea61b871b3eb0aef6fd5619c80550422fec595c0c4b232b73874992cca5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752566400,
      "headline": "Amgen: Great Starting Yield For This Wealth Compounder",
      "id": 135942663,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1126636461/image_1126636461.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Amgen combines patent protection, a robust pipeline, and strong execution for defensive investment.",
      "url": "https://finnhub.io/api/news?id=43424ea61b871b3eb0aef6fd5619c80550422fec595c0c4b232b73874992cca5"
    }
  },
  {
    "ts": null,
    "headline": "Draig Therapeutics Appoints Experienced Biotech Leader Douglas E. Williams, Ph.D. as Chair of its Board of Directors",
    "summary": "Douglas E. Williams, Ph.D. Chair of the Board of Directors Strong track record at executive and board level of building company value across all stages of development including supporting the development of multiple blockbuster medicines Cardiff, United Kingdom – 15 July 2025 – Draig Therapeutics (“Draig”), a clinical-stage company aiming to transform the treatment of neuropsychiatric diseases, today announces the appointment of Douglas E. Williams, Ph.D. as independent Chair of its Board of Dir",
    "url": "https://finnhub.io/api/news?id=cb0b56daaf668d75e90470e4d439c0e843a6615f148fefabf85074f7ee81ecdc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752566400,
      "headline": "Draig Therapeutics Appoints Experienced Biotech Leader Douglas E. Williams, Ph.D. as Chair of its Board of Directors",
      "id": 135937062,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Douglas E. Williams, Ph.D. Chair of the Board of Directors Strong track record at executive and board level of building company value across all stages of development including supporting the development of multiple blockbuster medicines Cardiff, United Kingdom – 15 July 2025 – Draig Therapeutics (“Draig”), a clinical-stage company aiming to transform the treatment of neuropsychiatric diseases, today announces the appointment of Douglas E. Williams, Ph.D. as independent Chair of its Board of Dir",
      "url": "https://finnhub.io/api/news?id=cb0b56daaf668d75e90470e4d439c0e843a6615f148fefabf85074f7ee81ecdc"
    }
  }
]